Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTumŪTKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTumŪTK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTumŪTKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTumŪTKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
2020BIOVICA INTERNATIONAL : FDA resource reallocation impacts DiviTumŪTKa timeline
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa in four posters at SABCS
AQ
2020BIOVICA INTERNATIONAL : completes 510(k) submission for DiviTumŪTKa to the FDA
AQ
2020BIOVICA INTERNATIONAL : Bulletin from the annual general meeting in Biovica
AQ
2020BIOVICA Q1 INTERIM REPORT : May-July 2020/2021
AQ
More most relevant news
All news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTumŪTKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTumŪTK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTumŪTKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTumŪTKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Press releases
01/18BIOVICA INTERNATIONAL : DiviTumŪTKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTumŪTK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTumŪTKa included in new UK breast cancer study
AQ
More press releases